---
title: "Low antenatal hepatitis B testing and incomplete infant birth‑dose coverage in Nigeria’s MTCT prev"
id: "medrxiv-6-contact-without-protection-high-antenatal-attendance-minimal-hepatitis-b"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-6-contact-without-protection-high-antenatal-attendance-minimal-hepatitis-b"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.15.26363185v1?rss=1"
published_at: "2026-09-18T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Low antenatal hepatitis B testing and incomplete infant birth‑dose coverage in Nigeria’s MTCT prev
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-6-contact-without-protection-high-antenatal-attendance-minimal-hepatitis-b
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.15.26363185v1?rss=1)
- **Published At:** 2026-09-18T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This national analysis used the 2023–24 Nigeria Demographic and Health Survey to build the first countrywide **mother-to-child transmission (MTCT)** prevention cascade for **hepatitis B** in Nigeria. - The analytic sample included 13,341 women with a most recent live birth in the preceding three years, each linked to that child’s immunisation record. - Antenatal care contact was common: 72% of mothers attended antenatal care. - Hepatitis B testing in antenatal care was rare: only 12.3% (95% CI 11.4–13.2) of mothers were tested; among those tested nearly all received a result, indicating the major loss occurred at the testing step, not result-return. - The infant **birth dose** coverage was 55.0% (95% CI 53.1–56.9), reported as 35 percentage points below the relevant elimination target. - Infant birth‑dose delivery appeared universal and non-targeted: its receipt was unrelated to whether the mother had antenatal hepatitis B testing. - The dominant correlate of an infant receiving the birth dose was **place of delivery**, not maternal testing. - Marked equity gaps were observed: antenatal testing varied from 2.6% in the poorest quintile to 32.4% in the richest, and testing was lowest in the North‑West region, where hepatitis B prevalence is highest. - The authors conclude Nigeria reaches many mothers through antenatal services but rarely converts that contact into hepatitis B testing; nationwide scale-up of free, antenatal testing focused on higher-burden northern regions would better translate existing contact into prevention.
## Clinical Analysis & Structured Key Points
Contact without protection: high antenatal attendance, minimal hepatitis B testing in Nigeria’s mother-to-child prevention cascade — how far from elimination? | medRxiv Skip to main content Contact without protection: high antenatal attendance, minimal hepatitis B testing in Nigeria’s mother-to-child prevention cascade — how far from elimination? View ORCID Profile Samson Ikenna Abanni , Bifom Melwin Ekure , View ORCID Profile Jean Omotosho doi: https://doi.org/10.64898/2026.09.15.26363185 Samson Ikenna Abanni 1 David Umahi Federal university of Health sciences; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Samson Ikenna Abanni For correspondence: abannisi{at}dufuhs.edu.ng Bifom Melwin Ekure 2 P&G Medical center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jean Omotosho 3 Margaret Lawrence University Teaching Hospital, Abuja, Nigeria Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jean Omotosho Abstract Info/History Metrics Data/Code Preview PDF Abstract Hepatitis B is a leading preventable cause of liver cancer, and in high-burden settings most chronic infection is acquired around birth. Nigeria carries Africa’s largest hepatitis B burden. Preventing mother-to-child transmission requires a chain of antenatal steps: testing pregnant women, acting on the result, and vaccinating the newborn. No nationally representative study has assembled these into a single prevention cascade. We built the first national hepatitis B mother-to-child prevention cascade for Nigeria and measured how far it falls from the World Health Organization’s triple-elimination targets. We analysed the 2023-24 Nigeria Demographic and Health Survey, the first Nigerian survey to carry both a maternal hepatitis B module and infant birth-dose records. Among 13,341 women with a most recent live birth in the preceding three years, each linked to that child’s immunisation record, we estimated coverage at each cascade step (antenatal attendance, hepatitis B testing in antenatal care, result received, and the infant birth dose) using complex-survey methods, and examined patterning by wealth, education, residence, travel time, and region. Although 72% of mothers attended antenatal care, only 12.3% (95% CI 11.4-13.2) were tested for hepatitis B there, and among the few tested almost all received a result: the loss fell at testing, not at result-return. The infant birth dose reached 55.0% (53.1-56.9), 35 points below target, and ran at a level unrelated to maternal testing, consistent with universal, non-targeted delivery; place of delivery, not maternal testing, was the dominant correlate of an infant receiving it. Both steps were steeply patterned: antenatal testing ranged from 2.6% in the poorest wealth quintile to 32.4% in the richest, and was lowest in the North-West, the zone with Nigeria’s highest prevalence. Nigeria already reaches most mothers through antenatal care but rarely uses that contact to test for hepatitis B, and the universal birth dose is only half delivered. The country is far from elimination, and furthest where the virus is commonest. Integrating hepatitis B testing into antenatal care, made free and weighted toward the highest-burden north, would convert contact already achieved into protection. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study is a secondary analysis of the publicly available, de-identified 2023–24 Nigeria Demographic and Health Survey. The survey received ethical approval from the National Health Research Ethics Committee of Nigeria and the ICF Institutional Review Board, and written informed consent was obtained from participants by the survey implementers. No additional ethical approval was required for this secondary analysis of public, de-identified data. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data underlying this study are third-party data owned by The DHS Program and are available at https://dhsprogram.com/data/ following free registration and a brief description of the intended analysis. The authors received no special access privileges and confirm that other researchers can access the data in the same manner. The variables and coding rules needed to reproduce every reported estimate are provided in S1 Table. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Posted September 18, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Contact without protection: high antenatal attendance, minimal hepatitis B testing in Nigeria’s mother-to-child prevention cascade — how far from elimination? Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Contact without protection: high antenatal attendance, minimal hepatitis B testing in Nigeria’s mother-to-child prevention cascade — how far from elimination? Samson Ikenna Abanni , Bifom Melwin Ekure , Jean Omotosho medRxiv 2026.09.15.26363185; doi: https://doi.org/10.64898/2026.09.15.26363185 Share This Article: Copy Citation Tools Contact without protection: high antenatal attendance, minimal hepatitis B testing in Nigeria’s mother-to-child prevention cascade — how far from elimination? Samson Ikenna Abanni , Bifom Melwin Ekure , Jean Omotosho medRxiv 2026.09.15.26363185; doi: https://doi.org/10.64898/2026.09.15.26363185 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Health Systems and Quality Improvement Subject Areas All Articles Addiction Medicine (618) Allergy and Immunology (903) Anesthesia (334) Cardiovascular Medicine (4822) Dentistry and Oral Medicine (479) Dermatology (416) Emergency Medicine (650) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1632) Epidemiology (15966) Forensic Medicine (33) Gastroenterology (1204) Genetic and Genomic Medicine (7057) Geriatric Medicine (733) Health Economics (1066) Health Informatics (5054) Health Policy (1436) Health Systems and Quality Improvement (1774) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16299) Intensive Care and Critical Care Medicine (1174) Medical Education (671) Medical Ethics (155) Nephrology (725) Neurology (7288) Nursing (368) Nutrition (1082) Obstetrics and Gynecology (1243) Occupational and Environmental Health (1005) Oncology (3613) Ophthalmology (1054) Orthopedics (398) Otolaryngology (457) Pain Medicine (472) Palliative Medicine (139) Pathology (709) Pediatrics (1805) Pharmacology and Therapeutics (737) Primary Care Research (768) Psychiatry and Clinical Psychology (5911) Public and Global Health (9767) Radiology and Imaging (2429) Rehabilitation Medicine and Physical Therapy (1455) Respiratory Medicine (1249) Rheumatology (642) Sexual and Reproductive Health (773) Sports Medicine (578) Surgery (780) Toxicology (107) Transplantation (305) Urology (292)
## Related Clinical Research

- [Kennedy renews attacks on vaccines at Children’s Health Defense conference](https://medichelpline.com/clinical-feed/stat-news-1-kennedy-renews-attacks-on-vaccines-at-children-s-health-defense-conference.md)
- [IeDEA 2026 Site Assessment: Protocol for a Cross-Sectional Survey of HIV Clinics and Service Deliv](https://medichelpline.com/clinical-feed/medrxiv-12-documenting-hiv-service-delivery-and-adoption-of-evidence-based-practices-in.md)
- [Serum Magnesium and Risk of Spontaneous Bacterial Peritonitis and Sepsis in Hospitalized Cirrhosis](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-association-of-serum-magnesium-levels-with-the-risk-of-spontaneous-bacterial.md)
- [Lyme disease incidence in England 2013–2024: updated multiplication factor and case trends](https://medichelpline.com/clinical-feed/medrxiv-13-trends-in-lyme-disease-incidence-in-england-2013-to-2024.md)
- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.